# Aclaris Therapeutics (ACRS) — Analyst Forecast

ACRS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/acrs/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 12 | 1 | 0 | 13 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 1, 2026 | Canaccord Genuity | Initiated Coverage | Buy | $10.00 |
| Jun 2, 2026 | LifeSci Capital | Initiated Coverage | Outperform | $13.00 |
| May 5, 2026 | Guggenheim | Initiated Coverage | Buy | $12.00 |
| May 5, 2026 | Piper Sandler | Maintained | Overweight | $11.00 |
| Apr 29, 2026 | Wedbush | Maintained | Outperform | $10.00 |
| Apr 16, 2026 | Oppenheimer | Initiated Coverage | Outperform | $10.00 |
| Mar 31, 2026 | Wedbush | Maintained | Outperform | $8.00 |
| Mar 19, 2026 | HC Wainwright & Co. | Maintained | Buy | $16.00 |
| Jan 28, 2026 | HC Wainwright & Co. | Maintained | Buy | $16.00 |
| Jan 21, 2026 | HC Wainwright & Co. | Maintained | Buy | $16.00 |
| Oct 20, 2025 | HC Wainwright & Co. | Maintained | Buy | $16.00 |
| Jul 10, 2025 | Piper Sandler | Initiated Coverage | Overweight | $6.00 |
| Jun 25, 2025 | HC Wainwright & Co. | Maintained | Buy | $16.00 |
| May 28, 2025 | Wedbush | Initiated Coverage | Outperform | $8.00 |
| May 14, 2025 | HC Wainwright & Co. | Maintained | Buy | $16.00 |
| May 9, 2025 | Scotiabank | Maintained | Sector Outperform | $9.00 |
| Mar 18, 2025 | Cantor Fitzgerald | Maintained | Overweight | — |
| Mar 7, 2025 | Scotiabank | Initiated Coverage | Sector Outperform | $15.00 |
| Dec 23, 2024 | HC Wainwright & Co. | Upgraded | Neutral → Buy | $20.00 |
| Nov 19, 2024 | BTIG | Upgraded | Neutral → Buy | $8.00 |

## Frequently Asked Questions

### Is ACRS a buy, sell, or hold?

Analysts covering Aclaris Therapeutics currently average a Buy rating: 12 buy, 1 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on ACRS?

On Sep 1, 2026, Canaccord Genuity initiated coverage of Aclaris Therapeutics at Buy with a price target of $10.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).